Morgan Stanley Lava Therapeutics Nv Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Lava Therapeutics Nv stock. As of the latest transaction made, Morgan Stanley holds 11,800 shares of LVTX stock, worth $15,104. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,800

Previous 8,500 38.82%

Holding current value

$15,104

Previous $8,000 75.0%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$0.91 - $1.44 $3,003 - $4,752	3,300 Added 38.82%	11,800 $14,000
Q4 2024 Feb 14, 2025	SELL	$0.98 - $2.04 $27,342 - $56,916	-27,900 Reduced 76.65%	8,500 $8,000
Q3 2024 May 14, 2025	BUY	$1.57 - $2.29 $32,656 - $47,632	20,800 Added 133.33%	36,400 $60,000
Q3 2024 Nov 14, 2024	BUY	$1.57 - $2.29 $32,656 - $47,632	20,800 Added 133.33%	36,400 $60,000
Q2 2024 May 14, 2025	BUY	$1.8 - $3.37 $12,780 - $23,927	7,100 Added 83.53%	15,600 $28,000
Q2 2024 Oct 17, 2024	BUY	$1.8 - $3.37 $9,720 - $18,198	5,400 Added 52.94%	15,600 $28,000
Q2 2024 Aug 14, 2024	BUY	$1.8 - $3.37 $9,720 - $18,198	5,400 Added 52.94%	15,600 $28,000
Q1 2024 Oct 17, 2024	SELL	$1.53 - $4.03 $8,262 - $21,762	-5,400 Reduced 34.62%	10,200 $33,000
Q1 2024 Aug 16, 2024	SELL	$1.53 - $4.03 $22,338 - $58,838	-14,600 Reduced 58.87%	10,200 $33,000
Q1 2024 May 15, 2024	SELL	$1.53 - $4.03 $22,338 - $58,838	-14,600 Reduced 58.87%	10,200 $33,000
Q4 2023 Aug 16, 2024	BUY	$1.17 - $1.58 $10,764 - $14,536	9,200 Added 58.97%	24,800 $39,000
Q4 2023 Feb 13, 2024	BUY	$1.17 - $1.58 $16,965 - $22,910	14,500 Added 140.78%	24,800 $39,000
Q3 2023 Nov 15, 2023	BUY	$1.47 - $2.06 $147 - $206	100 Added 0.98%	10,300 $15,000
Q2 2023 Aug 14, 2023	BUY	$1.4 - $2.6 $1,819 - $3,380	1,300 Added 14.61%	10,200 $20,000
Q1 2023 May 15, 2023	BUY	$1.59 - $3.97 $3,035 - $7,578	1,909 Added 27.31%	8,900 $14,000
Q4 2022 Feb 14, 2023	BUY	$3.37 - $7.31 $6,709 - $14,554	1,991 Added 39.82%	6,991 $24,000
Q3 2022 Nov 14, 2022	SELL	$2.34 - $4.75 $1,638 - $3,325	-700 Reduced 12.28%	5,000 $23,000
Q2 2022 Oct 27, 2022	BUY	$2.28 - $4.4 $6,611 - $12,760	2,900 Added 103.57%	5,700 $17,000
Q2 2022 Aug 15, 2022	BUY	$2.28 - $4.4 $6,611 - $12,760	2,900 Added 103.57%	5,700 $17,000
Q1 2022 Oct 27, 2022	SELL	$4.28 - $6.55 $12,412 - $18,995	-2,900 Reduced 50.88%	2,800 $12,000
Q1 2022 May 13, 2022	SELL	$4.28 - $6.55 $6,527 - $9,988	-1,525 Reduced 35.26%	2,800 $12,000
Q4 2021 Feb 14, 2022	BUY	$4.23 - $7.77 $18,294 - $33,605	4,325 New	4,325 $24,000

Others Institutions Holding LVTX

# of Institutions

Shares Held

4.93M

Call Options Held

50.2K

Put Options Held

200

View Full List

About LAVA Therapeutics NV

Ticker LVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,797,700
Market Cap $33M
Description
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer...

More about LVTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account